Global Perspectives: Current and Future Management of Breast Cancer

Practice changes and horizon openings from ESMO 2021 and beyond: triple-negative breast cancer, HR+, HER2+ early and metastatic breast cancer.

September 23 and 27, 2021
Nadia Harbeck


Nadia Harbeck, MD, PhD

Ludwig-Maximilians-University of Munich – Breast Center, Germany


Joyce A. O’Shaughnessy, MD

Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US

Faculty Members

Joseph Gligorov, MD, PhD
Tenon Hospital, Paris, France

Pierfranco Conte, MD
University of Padua, Italy

Guy Jerusalem, MD, PhD
University of Liège, Liège, Belgium

Hope Rugo, MD, FASCO
University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, US

Javier Cortes, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain

William Gradishar, MD
Northwestern Medical Group, Chicago, IL, US

Mark Pegram, MD
Stanford Women’s Cancer Center, Palo Alto, CA, US

Sample Report

Start discovering the insights

View Report


  • Current and New Treatments in HER2+ Early Breast Cancer (BC)
  • Current and New Treatments in HER2+ Metastatic Breast Cancer (mBC)
  • Current and Emerging Approaches in HR+, HER2– Early BC
  • Current and Emerging Approaches in HR+, HER2– mBC
  • Current and Emerging Approaches in Triple-Negative Breast Cancer (TNBC)
  • Novel Targets in Breast Cancer

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.